Literature DB >> 11561703

Resistance to treatment in Kala-azar: speciation of isolates from northeast India.

S Sundar1, K Pai, R Kumar, K Pathak-Tripathi, A A Gam, M Ray, R T Kenney.   

Abstract

Kala-azar in India is becoming increasingly difficult to treat, which may be due to the presence of species other than Leishmania donovani; Leishmania tropica was reported to cause the same clinical syndrome in the area. Over the past 3 years, we have collected samples from 241 patients with visceral leishmaniasis from across the region. Of the 189 isolates that grew on diphasic medium, 159 were successfully transferred to liquid medium for typing. Clinically, 80% of these were resistant to antimony. Lipophosphoglycan-specific monoclonal antibodies were used to distinguish the 2 species by agglutination of promastigotes; all 159 were shown to be L. donovani. Eighty-three isolates were confirmed to be L. donovani by isoenzyme analysis, by amplification of kinetoplast DNA, or both, in comparison with multiple reference strains; none were L. tropica. Thus, the rising incidence of clinical resistance to treatment is unlikely to be due to a different species causing kala-azar in north Bihar.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561703     DOI: 10.4269/ajtmh.2001.65.193

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

Review 1.  Laboratory diagnosis of visceral leishmaniasis.

Authors:  Shyam Sundar; M Rai
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

2.  Reduced antimony accumulation in ARM58-overexpressing Leishmania infantum.

Authors:  Carola Schäfer; Paloma Tejera Nevado; Dorothea Zander; Joachim Clos
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Detection, differentiation, and quantitation of pathogenic leishmania organisms by a fluorescence resonance energy transfer-based real-time PCR assay.

Authors:  Alexandra Schulz; Katja Mellenthin; Gabriele Schönian; Bernhard Fleischer; Christian Drosten
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  Management of visceral leishmaniasis in rural primary health care services in Bihar, India.

Authors:  E Hasker; S P Singh; P Malaviya; R P Singh; R Shankar; M Boelaert; S Sundar
Journal:  Trop Med Int Health       Date:  2010-07       Impact factor: 2.622

6.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 7.  Leishmania antimony resistance: what we know what we can learn from the field.

Authors:  Khatima Aït-Oudhia; Elodie Gazanion; Baptiste Vergnes; Bruno Oury; Denis Sereno
Journal:  Parasitol Res       Date:  2011-07-29       Impact factor: 2.289

8.  Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting system.

Authors:  P Malaviya; R P Singh; S P Singh; E Hasker; B Ostyn; R Shankar; M Boelaert; S Sundar
Journal:  Trop Med Int Health       Date:  2011-05-30       Impact factor: 2.622

9.  A novel class of developmentally regulated noncoding RNAs in Leishmania.

Authors:  Carole Dumas; Conan Chow; Michaela Müller; Barbara Papadopoulou
Journal:  Eukaryot Cell       Date:  2006-10-27

10.  Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.

Authors:  Diego A Goyeneche-Patino; Liliana Valderrama; John Walker; Nancy G Saravia
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.